Key result
Combined heterozygous FVL and FII 20210A mutation was associated with a higher risk of pregnancy-associated VTE compared to FII mutation alone (17.8% vs 6.2%; RR 2.9, 95% CI 1.4-5.9, P=0.003).
Why the study?
Does combined heterozygous FVL and FII mutation increase the risk of pregnancy-associated VTE compared to FII mutation alone?
Population
129 women evaluated for VTE risk in the absence of prophylaxis, including 47 women with combined…
Comparison
Combined heterozygous factor V Leiden plus… vs Heterozygous FII single gene mutation alone
Design
Cohort
Authors
Loading...
May support individualized VTE risk counseling in pregnancy; leaves open whether intensified prophylaxis improves outcomes.
Cohort (n=129)
Does combined heterozygous FVL and FII mutation increase the risk of pregnancy-associated VTE compared to FII mutation alone?
Relative Risk: 2.9 (95% CI 1.4–5.9)
Absolute Event Rate: 17.8% vs 6.2%
p-value: p=0.003
Women with combined heterozygous FVL and FII mutations have a significantly higher risk of pregnancy-associated VTE compared to those with FII mutation alone, suggesting a need for targeted prophylaxis.
Samama et al. (2003) conducted a cohort in Pregnancy-associated venous thromboembolism (VTE) (n=129). Combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210A mutation vs. Heterozygous FII mutation alone was evaluated on Venous thromboembolism (VTE) (RR 2.9, 95% CI 1.4-5.9, p=0.003). Combined heterozygous FVL and FII 20210A mutation was associated with a higher risk of pregnancy-associated VTE compared to FII mutation alone (17.8% vs 6.2%; RR 2.9, 95% CI 1.4-5.9, P=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: